Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab-Ipilimumab Induction in Advanced Cervical Cancer
NCT05492123Phase 2Recruiting
- Sponsor
- Hospital Israelita Albert Einstein
- Start
- Aug 2022
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nivolumab and ipilimumab in Cervical Cancer (CC) (2 arms), sponsored by Hospital Israelita Albert Einstein. Primary endpoint: Progression-Free Survival at 3 years. Started Aug 2022; status: recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT05492123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05492123.